<DOC>
	<DOC>NCT00152503</DOC>
	<brief_summary>This trial will evaluate the efficacy and safety of ucb 44212 as add-on therapy in subjects with focal epilepsy.</brief_summary>
	<brief_title>Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>Males/Females from 18 to 65 years of age (minimum body weight of 40 kg) Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures whether or not secondarily generalized. Subjects who have been treated for epilepsy for â‰¥6 months and are currently uncontrolled while being treated with 13 concomitant AED(s), inclusive of LEV. Female subjects without childbearing potential or those who are using an acceptable contraceptive method Seizures occurring in clusters. Status epilepticus within 6 months of Visit 1. History of nonepileptic seizures Subjects on vigabatrin Subjects on felbamate, unless treatment has been continuous for &gt;2 years Ongoing psychiatric disease other than mild controlled disorders. Subjects with clinically significant organ dysfunction Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients Pregnant or lactating women. Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant AEDs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Epilepsy, Partial Onset Seizures, Seletracetam</keyword>
</DOC>